Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.

[1]  Wen Jiang,et al.  Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). , 2017, International journal of radiation oncology, biology, physics.

[2]  K. Walter,et al.  Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era: The University of Rochester Experience , 2017, American journal of clinical oncology.

[3]  Jennifer S. Yu,et al.  Use of Concurrent TKIs With SRS is Associated With an Increased Rate of Radiation Necrosis Among Patients With Renal Cell Carcinoma Brain Metastasis , 2017 .

[4]  P. Brown,et al.  The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. , 2017, International journal of radiation oncology, biology, physics.

[5]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[6]  Shenhong Wu,et al.  New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy , 2017, Journal of Hematology & Oncology.

[7]  R. Motzer,et al.  Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.

[8]  P. Brown,et al.  The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.

[9]  Volker W Stieber,et al.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.

[10]  Marchetti Paolo,et al.  Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy. , 2016, Therapeutic advances in medical oncology.

[11]  G. Cartenì,et al.  Recent developments in second and third line therapy of metastatic renal cell carcinoma , 2016, Expert review of anticancer therapy.

[12]  K. Ballman,et al.  Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Porta,et al.  Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma , 2015, British Journal of Cancer.

[14]  N. Gebauer,et al.  Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. , 2015, Anticancer research.

[15]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[16]  R. Labianca,et al.  Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial , 2015, Oncology.

[17]  C. Yee,et al.  The Effect of Radiation on the Immune Response to Cancers , 2014, International journal of molecular sciences.

[18]  T. Choueiri,et al.  Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. , 2013, Clinical genitourinary cancer.

[19]  Meihua Wang,et al.  A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. , 2013, International journal of radiation oncology, biology, physics.

[20]  N. Haseke,et al.  Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. , 2012, Urologic oncology.

[21]  E. Shaw,et al.  The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. , 2012, Journal of neurosurgery.

[22]  M. Menon,et al.  Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Jonasch,et al.  Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma , 2011, Cancer.

[25]  N. Haseke,et al.  Simultaneous anti‐angiogenic therapy and single‐fraction radiosurgery in clinically relevant metastases from renal cell carcinoma , 2011, BJU international.

[26]  C. Porta,et al.  Sunitinib in metastatic renal cell carcinoma patients with brain metastases , 2011, Cancer.

[27]  L. Collette,et al.  Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Szczylik,et al.  Incidence of brain metastases in renal cell carcinoma treated with sorafenib. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[31]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[32]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[33]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Twijnstra,et al.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.

[35]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.